This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
Amedisys (AMED) Q2 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Robust year-over-year growth in Medicare and non-Medicare revenues aids Amedisys' (AMED) Home Health and Hospice divisions.
Hologic (HOLX) Beats on Q3 Earnings, Ups '19 Revenue View
by Zacks Equity Research
Hologic's (HOLX) strong top-line growth in Q3 is led by a solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics.
McKesson (MCK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) Q1 results benefit from higher revenues and solid show by U.S. Pharmaceutical and Specialty, and Medical-Surgical Solutions.
AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Higher revenues, segmental growth and raised 2019 EPS outlook benefit AmerisourceBergen's (ABC) Q3 earnings.
Luminex (LMNX) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Higher revenues and solid performance across System Sales, Consumable Sales and Royalty Revenues benefit Luminex's (LMNX) Q2 earnings. However, gross margin contraction remains a woe.
CONMED (CNMD) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q2 earnings. However, high long-term debt remains a concern.
ABIOMED (ABMD) Q1 Earnings Top Estimates, Sales Rise in Japan
by Zacks Equity Research
ABIOMED (ABMD) slashes revenue guidance for fiscal 2020.
IDEXX (IDXX) Beats Q2 Earnings Estimates, Lifts EPS Guidance
by Zacks Equity Research
IDEXX's (IDXX) top line in the second quarter gains from strong sales at the CAG business.
Surmodics (SRDX) Q3 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q3.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Buoyed by a solid second quarter, Masimo (MASI) raises its 2019 guidance.
Fresenius Medical (FMS) Q2 Earnings Miss Estimates, Down Y/Y
by Zacks Equity Research
Strong segmental performance and solid 2019 EPS outlook benefit Fresenius Medical's (FMS) Q2 earnings. However, soft performance at Latin America remains a woe.
NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
NuVasive (NUVA) witnesses balanced revenue growth across majority of key operating segments.
QIAGEN (QGEN) Misses Q2 Earnings Estimates, Lowers View
by Zacks Equity Research
QIAGEN (QGEN) registers revenue growth across majority of its geographies in Q2.
PerkinElmer (PKI) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Higher revenues and growth in Diagnostics segment benefit PerkinElmer's (PKI) Q2 earnings. However, forex remains a woe.
Ecolab (ECL) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Ecolab (ECL) gains from solid segmental contributions in the second quarter. It retains 2019 EPS view.
Baxter (BAX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Baxter (BAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Baxter (BAX) Beats on Q2 Earnings & Revenues, Ups EPS View
by Zacks Equity Research
Higher revenues, growth in APAC and raised 2019 EPS outlook benefit Baxter's (BAX) Q2 earnings. However, weak performance at Clinical Nutrition and margin contraction remains a woe.
Baxter International (BAX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 9.88% and 1.91%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for Jul 25: SYK, BAX & More
by Urmimala Biswas
Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.
Baxter (BAX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter (BAX) expects second-quarter revenues to decline 2% on a reported basis.
Baxter International (BAX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS
Trump's Order on Kidney Care Lifts These Dialysis Stocks
by Tirthankar Chakraborty
Dialysis stocks move north after Trump signs an executive order designed to reform the nation's kidney treatment industry.
Patterson Companies' (PDCO) Earnings Miss Estimates in Q4
by Zacks Equity Research
Patterson Companies' (PDCO) Q4 results benefit from higher revenues, gross margin expansion and solid show by Animal Health segment.
Top Analyst Reports for ExxonMobil, Oracle & ADP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM), Oracle (ORCL) and ADP (ADP).